Respiratory syncytial virus (RSV) is not well known outside medical circles, yet most people have probably suffered from it in childhood, as it is the most common cause of severe respiratory illness in infants and children worldwide. The elderly and people with weakened immune systems are also vulnerable to RSV infection. While most people’s symptoms are mild, it can result in pneumonia and 3.4 million cases annually require hospitalisation.
Respiratory Syncytial Virus Consortium in Europe
RESCUE is funded by the Innovative Medicines Initiative Joint Undertaking, cofunded by the European Commission FP7 Programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA).
The goal of the RESCEU project is to gather information on the scale of RSV infection in Europe and its economic impacts. It will then use this information to design best practice guidelines to improve the way RSV cases are monitored in Europe, and to shape future vaccination programs. The team will also gather and analyse patient samples to identify biological markers associated with severe RSV infection. This information could aid in diagnosis and facilitate the development of new treatments and vaccines.
As a partner, Penta is contributing to health care systems data collection and leads activities around networking and linkage to Regulatory Authorities. In addition, through our collaboration with the Laboratory of Mass Spectrometry and Metabolomics, Department of Women’s and Children’s Health, University of Padova, Penta is supporting the metabolomic analysis for biomarkers discovery and analysis of complex biomarker data sets.
This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement Nº 116019. This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA